Accordingly, in the present analysis, using data from CREDENCE trial (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; ClinicalTrials.gov Identifier: NCT02065791), we sought to investigate the association of IGF-1, IGFBP-3 and IGF-1/IGFBP-3 ratio with incident cardio-renal outcomes and evaluated effect of canagliflozin on their concentrations. This evidence concerns the gene IGF1 and kidney disorder.